title: [Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management].
abstract: For secondary prevention of acute coronary syndrome, guidelines recommend dual antiplatelet therapy with acetylsalicylic acid and a P2Y12 receptor antagonist such as clopidogrel, prasugrel or ticagrelor for a period of 12 months. Premature discontinuation of dual antiplatelet therapy is associated with an increased risk of ischaemic events. However, antiplatelet therapy is also associated with an increased risk of bleeding that should not be under- or overestimated. To ensure an optimal care of patients receiving dual antiplatelet therapy after an acute coronary syndrome, an interdisciplinary group of experienced experts in the fields of cardiology, cardiac surgery, gastroenterology, anaesthesiology, intensive care and haemostaseology gathered bleeding-related information and developed recommendations relevant to daily clinical practice. These include the significance of bleeding events in the course of treatment, measures for bleeding prevention and the adequate care of patients with bleedings.
authors.forename: U
authors.initials: U
authors.lastname: Zeymer
authors.forename: J
authors.initials: J
authors.lastname: Koscielny
authors.forename: C
authors.initials: C
authors.lastname: von Heymann
authors.forename: M
authors.initials: M
authors.lastname: Spannagl
authors.forename: J
authors.initials: J
authors.lastname: Labenz
authors.forename: J
authors.initials: J
authors.lastname: Cremer
authors.forename: E
authors.initials: E
authors.lastname: Giannitsis
authors.forename: H
authors.initials: H
authors.lastname: Darius
authors.forename: F
authors.initials: F
authors.lastname: Goss
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications* / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D010348:Patient Care Team / Q000458:organization & administration; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D001241:Aspirin